Pharmacodynamic targets, class effects and therapeutic limits
Connect a target to an effect
Pharmacodynamics describes drug effects and the relationship between exposure and response. Receptors, enzymes, ion channels and transporters provide different targets. An agonist can activate a receptor response, whereas an antagonist can oppose an agonist under the relevant conditions. Affinity, potency and maximal efficacy describe different properties. A more potent drug is not automatically more effective, safer or the appropriate choice for a particular patient.
Interpret concentration-response models
A competitive reversible antagonist can shift an idealized agonist response curve without necessarily changing its maximum when sufficient agonist is available. Other mechanisms can alter the maximum or have different time dependence. These models require stated assumptions; a simplified curve is not a complete description of every organ or clinical outcome. Receptor selectivity can vary with concentration, and a class name does not guarantee absolute specificity at every exposure.
Relate mechanisms to benefits and harms
Beta-lactam antibacterials act through relevant bacterial cell-wall targets, while other antimicrobial classes affect protein synthesis or different pathways. A microbial mechanism does not make an antibacterial a treatment for the virus itself. Cardiovascular, endocrine, nervous-system and inflammatory medicines likewise require a target-based explanation rather than memorizing an isolated brand name. Mechanism can predict some adverse effects or interactions but cannot exclude every unusual or patient-specific reaction.
Preserve the clinical decision boundary
Indication, disease severity, comorbidities, pregnancy, organ function, other medicines and patient preferences influence treatment selection. A drug effective in a trial can be inappropriate for a patient with a relevant contraindication or a different therapeutic objective. Adverse-effect management requires assessment of severity and alternatives, not an automatic instruction to stop every long-term medicine without coordination. Describe what an examination scenario supplies and what remains unknown. This chapter develops class mechanisms and interpretation, not universal prescriptions, first-line regimens, antidote instructions or dose schedules. Use current product information and appropriate clinical guidance for actual care, with monitoring and follow-up matched to the intended benefit and possible harm.